News

Sep 24 2025

Precision Psychiatry on the Horizon: Biomarkers, Psychoplastogens, and Predictive EEG

By James La Rossa Brief Bulletins from the Field, We Know Psychiatry

Key Updates Biomarker-Stratified Antidepressant ResponseA randomized trial in JAMA Psychiatry (Sept 2025) found that patients with treatment-resistant depression who carried the ANK3 biomarker had improved outcomes with liafensine, suggesting potential…

Sep 15 2025

Love0

Rapid-Acting, Novel Modalities & Regulatory Wins: Where Psychopharmacology Stands in Late 2025

By James La Rossa Brief Bulletins from the Field, We Know Psychiatry

From Psychedelics to Mechanism-Driven Precision: Recent Shifts in Depression Treatment What if we could reliably predict which antidepressant will work for a patient before waiting four weeks of trial-and-error? As…

Jul 23 2025

Love0

US Abortion Restrictions and the Neuropsychiatric Health of Pregnant Individuals and Families

By James La Rossa Brief Bulletins from the Field, Featured, We Know Psychiatry

Recent changes in the legal landscape in the United States have affected access to abortion, and this restricted access has profound effects on both physical and mental health of reproductive-aged…

Jul 22 2025

Love0

FDA Reviews Brexpiprazole-Sertraline Combo for PTSD

By James La Rossa Brief Bulletins from the Field, Featured, We Know Psychiatry

The FDA’s Psychopharmacologic Drugs Advisory Committee is evaluating a New Drug Application (NDA) for a combination of brexpiprazole and sertraline as a potential treatment for posttraumatic stress disorder (PTSD). If…

Jul 13 2025

Love0

Johnson & Johnson Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

By James La Rossa Brief Bulletins from the Field, We Know Psychiatry

Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting…

Jul 04 2025

Love0

Autoimmune Diseases Linked to Increased Risk for Mood Disorders

By James La Rossa Brief Bulletins from the Field, We Know Psychiatry

A study of 1.5 million UK adults found that autoimmune diseases are linked to a nearly twofold increase in the risk for mood disorders such as depression, anxiety, and bipolar…

Jul 04 2025

Love0

Semaglutide May Lower Dementia Risk in T2 Diabetes

By James La Rossa Brief Bulletins from the Field, We Know Psychiatry

Semaglutide, a medication for type 2 diabetes (T2D), is associated with a 20%-46% reduced risk for Alzheimer's disease-related dementia compared with other antidiabetic drugs. A study analyzed electronic health records…

Jun 30 2025

Love0

New Guidelines Aim to Standardize Psychedelic Clinical Trials

By James La Rossa Articles in Press, We Know Psychiatry

An international panel of 89 experts from 17 countries has developed new guidelines—Reporting of Setting in Psychedelic Clinical Trials (ReSPCT)—to standardize how psychedelic clinical trials report 'set and setting,' the…

Jun 30 2025

Love0

Weekly Oral Risperidone Pill Shows Promise in Schizophrenia

By James La Rossa Brief Bulletins from the Field, We Know Psychiatry

A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or schizoaffective disorder.…

Jun 30 2025

Love0

Early Psychological Therapy Improves Post-Stroke Depression and Anxiety

By James La Rossa Brief Bulletins from the Field, We Know Psychiatry

Psychological therapy has been shown to significantly alleviate depression and anxiety in stroke survivors, particularly when initiated within six months of the stroke event. In a study involving over 7,000…

Precision Psychiatry on the Horizon: Biomarkers, Psychoplastogens, and Predictive EEG

Rapid-Acting, Novel Modalities & Regulatory Wins: Where Psychopharmacology Stands in Late 2025

US Abortion Restrictions and the Neuropsychiatric Health of Pregnant Individuals and Families

FDA Reviews Brexpiprazole-Sertraline Combo for PTSD

Johnson & Johnson Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

Autoimmune Diseases Linked to Increased Risk for Mood Disorders

Semaglutide May Lower Dementia Risk in T2 Diabetes

New Guidelines Aim to Standardize Psychedelic Clinical Trials

Weekly Oral Risperidone Pill Shows Promise in Schizophrenia

Early Psychological Therapy Improves Post-Stroke Depression and Anxiety

PSYCH. BULLETIN

ASSESSMENT TOOLS

QUICK LINKS